Cipla expects to commence supplies to US from China plant later this year
Cipla expects to commence supplies to the US market from its China facility in the second half of the current fiscal after getting approval from the American health regulator, according to its MD and global CEO Umag Vohra. Addressing shareholders in the company's Annual Report for 2023-24, he noted that the company is working with the USFDA to resolve issues with its various domestic plants.
#Budget 2024 with ET
Budget Highlights: Your 2-minute guide
What's cheaper and what's costlier? Here's the list
New slabs announced in new income tax regime
«Although we saw challenging phases with USFDA audits, I am glad to report that our China facility cleared the USFDA audit and is expected to supply to the US by the second half of FY 2024- 25,» Vohra said.
Sharing updates about other plants, he noted that the facilities of Patalganga and Kurkumbh in India were also cleared with a VAI (voluntary action indicated).
«Our Goa site was issued observations and our Indore plant is currently being remediated. Finding resolution for these regulatory issues continues to be our top priority,» Vohra said.
The company has worked extensively to remediate its sites, creating a blueprint for solid expansion in India and is working closely with the USFDA to remediate these sites, he added.
Vohra informed shareholders that the company is looking to target new therapeutic areas like obesity-related diseases, and liver conditions while investing heavily in tech-based solutions for various ailments.
The Mumbai-based company is also looking
